StreetInsider.com News Articles

Form SCHEDULE 13G Jade Biosciences, Inc. Filed by: Paradigm Biocapital Advisors LP

Fri, 17 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26784362.html

Form SCHEDULE 13G Jade Biosciences, Inc. Filed by: Paradigm Biocapital Advisors LP

Fri, 17 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26784362.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Janus Henderson Group Ltd.

Wed, 08 Jul 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260708/26748492.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Janus Henderson Group Ltd.

Wed, 08 Jul 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260708/26748492.html

Jade Biosciences licenses antibody program from Paragon Therapeutics

Wed, 01 Jul 2026 17:13:35 -0400

Jade Biosciences (NASDAQ: JBIO) entered into a license agreement with Paragon Therapeutics on June 29, 2026, securing worldwide exclusive rights to develop and commercialize certain monospecific antibodies targeting an undisclosed biological target across all human disease therapeutic areas.

Under the agreement, Jade Biosciences is obligated to pay Paragon up to $22.0 million in development and regulatory milestone payments. A $1.5 million development candidate nomination fee was paid in January 2026, and a $2.5 million payment is due upon first dosing of a patient in a Phase 1 clinical trial.

The company is also obligated to pay sublicensing fees of up to approximately

Form 8-K Jade Biosciences, Inc. For: Jun 29

Wed, 01 Jul 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260701/26721546.html

Form 8-K Jade Biosciences, Inc. For: Jun 29

Wed, 01 Jul 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260701/26721546.html

Form 4 Jade Biosciences, Inc. For: Jun 25 Filed by: Eisner Mark

Fri, 26 Jun 2026 21:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26700322.html

Form 4 Jade Biosciences, Inc. For: Jun 25 Filed by: Eisner Mark

Fri, 26 Jun 2026 21:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26700322.html

Form 3 Jade Biosciences, Inc. For: Jun 25 Filed by: Eisner Mark

Fri, 26 Jun 2026 21:11:00 -0400

si-local-file:///var/storage/secattach/20260626/26700315.html

Form 3 Jade Biosciences, Inc. For: Jun 25 Filed by: Eisner Mark

Fri, 26 Jun 2026 21:11:00 -0400

si-local-file:///var/storage/secattach/20260626/26700315.html

Form 8-K Jade Biosciences, Inc. For: Jun 25

Fri, 26 Jun 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260626/26694960.html

Form 8-K Jade Biosciences, Inc. For: Jun 25

Fri, 26 Jun 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260626/26694960.html

Jade Biosciences names Mark Eisner to its board of directors

Fri, 26 Jun 2026 07:01:23 -0400

Jade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Mark Eisner, M.D., M.P.H., to its board of directors, effective June 25, 2026.

Eisner has more than 25 years of experience in clinical development and immunology. He most recently served as executive vice president and chief medical officer of Vir Biotechnology, where he oversaw clinical development, regulatory sciences, and medical affairs.

Prior to that role, he served as chief medical officer at Sonoma Biotherapeutics and FibroGen, and spent nearly 11 years at Genentech/Roche, including as senior vice president and global head of product development for immunology, infectious disease, and ophthalmology. Before entering the

Jade Biosciences names Mark Eisner to its board of directors

Fri, 26 Jun 2026 07:01:23 -0400

Jade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Mark Eisner, M.D., M.P.H., to its board of directors, effective June 25, 2026.

Jade Biosciences names Mark Eisner to its board of directors

Fri, 26 Jun 2026 07:01:23 -0400

Jade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Mark Eisner, M.D., M.P.H., to its board of directors, effective June 25, 2026.

Jade Biosciences names Mark Eisner to its board of directors

Fri, 26 Jun 2026 07:01:23 -0400

Jade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Mark Eisner, M.D., M.P.H., to its board of directors, effective June 25, 2026.

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors